Summit Therapeutics Faces Mixed Results in Lung Cancer Drug Trials
31.05.2025, 04:00
Summit Therapeutics has experienced a volatile response following the results of its Phase III trial for ivonescimab, a drug aimed at treating lung cancer. Despite achieving significant progression-free survival (PFS) outcomes, the therapy missed crucial overall survival endpoints, causing a decline...